Importantly, our findings indicate that treatment with Sorafenib effectively suppresses ESCC tumor growth by upregulating TRIM21 transcription, suggesting that Sorafenib may offer a superior therapeutic option for certain patients with ESCC. The gene discussed is TRIM21; the disease is esophageal squamous cell carcinoma.